Trade Finch Therapeutics Group, Inc. - FNCH CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0724 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.2838 |
| Open | 2.1938 |
| 1-Year Change | 348.35% |
| Day's Range | 2.0138 - 2.2438 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 2.2138 | 0.0200 | 0.91% | 2.1938 | 2.2438 | 2.0138 |
| Apr 24, 2024 | 2.2838 | -0.2100 | -8.42% | 2.4938 | 2.5338 | 2.2438 |
| Apr 23, 2024 | 2.7638 | 0.4200 | 17.92% | 2.3438 | 3.0338 | 2.3438 |
| Apr 22, 2024 | 2.2338 | 0.0700 | 3.24% | 2.1638 | 2.2938 | 2.0838 |
| Apr 19, 2024 | 2.1438 | -0.1300 | -5.72% | 2.2738 | 2.2738 | 2.1338 |
| Apr 18, 2024 | 2.2338 | -0.1000 | -4.28% | 2.3338 | 2.3838 | 2.0638 |
| Apr 17, 2024 | 2.4338 | -0.5900 | -19.51% | 3.0238 | 3.0238 | 2.2838 |
| Apr 16, 2024 | 3.0338 | 0.9400 | 44.89% | 2.0938 | 3.2938 | 2.0538 |
| Apr 15, 2024 | 2.2138 | 0.0400 | 1.84% | 2.1738 | 2.3038 | 1.8838 |
| Apr 12, 2024 | 1.9838 | -0.3500 | -15.00% | 2.3338 | 2.3338 | 1.8638 |
| Apr 11, 2024 | 2.3338 | -0.0400 | -1.69% | 2.3738 | 2.3838 | 2.1838 |
| Apr 10, 2024 | 2.4338 | 0.0500 | 2.10% | 2.3838 | 2.4338 | 2.3838 |
| Apr 9, 2024 | 2.4538 | 0.0700 | 2.94% | 2.3838 | 2.4538 | 2.3738 |
| Apr 8, 2024 | 2.2138 | 0.0000 | 0.00% | 2.2138 | 2.2138 | 2.2138 |
| Apr 5, 2024 | 2.1338 | -0.2000 | -8.57% | 2.3338 | 2.3338 | 2.1338 |
| Apr 4, 2024 | 2.2638 | -0.0600 | -2.58% | 2.3238 | 2.3338 | 2.1838 |
| Apr 3, 2024 | 2.3338 | -0.0400 | -1.69% | 2.3738 | 2.3738 | 2.3238 |
| Apr 2, 2024 | 2.3938 | -0.0300 | -1.24% | 2.4238 | 2.4538 | 2.3138 |
| Apr 1, 2024 | 2.4838 | 0.0000 | 0.00% | 2.4838 | 2.5238 | 2.4838 |
| Mar 28, 2024 | 2.6238 | 0.0000 | 0.00% | 2.6238 | 2.6238 | 2.6238 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Finch Therapeutics Group, Inc. Company profile
About Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). It is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Finch Therapeutics Group Inc revenues increased from $5.9M to $17.7M. Net loss increased 49% to $39.1M. Revenues reflect Collaboration revenue increase from $5.6M to $17.7M. Higher net loss reflects Research and development - Balancing val increase of 69% to $41.3M (expense), General and administrative - Balancing increase of 93% to $14.6M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
75 State Street
Suite 100
BOSTON
MASSACHUSETTS 02109
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com